Cargando…
Simvastatin offers new prospects for the treatment of Duchenne muscular dystrophy
Duchenne muscular dystrophy (DMD) is the most common and severe inherited neuromuscular disorder. DMD is caused by mutations in the gene encoding the dystrophin protein in muscle fibers. Dystrophin was originally proposed to be a structural protein that protected the sarcolemma from stresses produce...
Autores principales: | Whitehead, Nicholas P., Kim, Min Jeong, Bible, Kenneth L., Adams, Marvin E., Froehner, Stanley C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4838314/ https://www.ncbi.nlm.nih.gov/pubmed/27141415 http://dx.doi.org/10.1080/21675511.2016.1156286 |
Ejemplares similares
-
Simvastatin provides long‐term improvement of left ventricular function and prevents cardiac fibrosis in muscular dystrophy
por: Kim, Min J., et al.
Publicado: (2019) -
The immune system in Duchenne muscular dystrophy: Friend or foe
por: Villalta, S Armando, et al.
Publicado: (2015) -
Drosophila as a starting point for developing therapeutics for the rare disease Duchenne Muscular Dystrophy
por: Pantoja, Mario, et al.
Publicado: (2013) -
Muscle-specific microRNAs as biomarkers of Duchenne Muscular Dystrophy progression and response to therapies
por: Giordani, L, et al.
Publicado: (2014) -
Facioscapulohumeral muscular dystrophy: Are telomeres the end of the story?
por: Stadler, Guido, et al.
Publicado: (2013)